Coronavirus Disease 2019: Considerations for Health Technology Assessment From the National Centre for Pharmacoeconomics Review Group

• Published in: Value in health Vol. 23; no. 11; pp. 1423 - 1426
• Main Authors: Leahy, Joy, Hickey, Conor, McConnell, David, Cassidy, Owen, Trela-Larsen, Lea, Barry, Michael, Tilson, Lesley, McCullagh, Laura
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.11.2020; Elsevier Science Ltd; ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc
• Subjects: Advisory Committees; Applicants; Betacoronavirus; budget impact; Budgets; Clinical assessment; Clinical research; Clinical trials; Coronavirus Infections - drug therapy; Coronaviruses; cost-effectiveness; COVID-19; Discontinued; Economics; Economics, Pharmaceutical; evidence synthesis; Extrapolation; Health care expenditures; Health technology assessment; Humans; Internal Medicine; Medical technology; Medical treatment; Pandemics; Patients; Pharmacoeconomics; Pharmacology; Pneumonia, Viral - drug therapy; Public Health; Quality of Life; SARS-CoV-2; Sensitivity analysis; Technology assessment; Technology Assessment, Biomedical; Themed Section: COVID-19; treatment discontinuation; treatment effect; Treatment Outcome; Uncertainty; Withholding Treatment; COVID-19; health technology assessment; cost-effectiveness; extrapolation; treatment effect; treatment discontinuation; evidence synthesis; budget impact

It is expected that the coronavirus disease 2019 (COVID-19) pandemic will leave large deficits in the budgets of many jurisdictions. Funding for other treatments, in particular new treatments, may become more constrained than previously expected. Therefore, a robust health technology assessment (HTA...